Our immunotherapy allies

免疫疗法的承诺，即刺激机体的免疫系统来对抗癌症的药物，可以通过观察最近与领先的制药公司形成合作发展的见证字符串。

MD安德森的partnerships include: Johnson & Johnson Innovation, LLC, and its affiliate Janssen Biotech, Inc., MedImmune, Pfizer and GlaxoSmithKline. The agreements are part of an ambitious plan to collaborate with industry leaders to more rapidly develop cancer immunotherapies as part of MD Anderson's Moon Shots Program.

这些协议结合MD安德森的能力，以确定有前途的药物靶标与行业专业知识，这些目标移动到临床显著端点，其中更有效的药物可以开发。

"Our new collaborations are different from traditional agreements because they allow both parties to work on any project they deem appropriate without additional budgets," saidFerran Prat, Ph.D., J.D., and vice president of strategic industry ventures.

“我们为我们的制药和生物技术合作者获得国家的最先进的设施，新的研究方案进行临床试验开到我们的大和多样化的患者群，并有机会工作，在免疫领域的领导者，”普拉特补充道。188bet体育网址

MD安德森通过创建一个支持它的登月计划，该机构10年来致力于更快地开发治疗等干预措施，以减少显著癌症死亡的平台公认的免疫疗法的潜力。

"We welcome the opportunity to work closely with these companies to build upon the early successes of immunotherapy by extending this approach to many types of cancer and exploring ways to improve treatment effectiveness," said James Allison, Ph.D., chair of Immunology and executive director of the immunotherapy platform.

MD安德森的immunotherapy efforts共主角由吉姆·阿利森博士帕特里克HWU，医学博士和Padmanee夏尔马，医学博士，博士